Glimepirida Mabo

Glimepirida Mabo is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Glimepiride works by stimulating insulin release from pancreatic β‑cells, helping to lower blood glucose in patients with type 2 diabetes mellitus. The product is intended for use under medical supervision and regular follow‑up.

Glimepirida Mabo is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan.

- As monotherapy in patients whose diet and exercise alone do not achieve glycemic control. - In combination with metformin when additional glucose lowering is needed. - As adjunct to other oral antidiabetic agents (e.g., DPP‑4 inhibitors) under physician guidance. - To help achieve individualized HbA1c targets when lifestyle measures are insufficient.

The safety profile of Glimepirida Mabo includes a range of reported adverse effects, which are classified by frequency and severity.

Common: - Mild hypoglycemia (especially if meals are missed). - Nausea or abdominal discomfort. - Headache. - Dizziness. - Weight gain.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, pruritus, or angioedema. - Hepatotoxicity (elevated liver enzymes). - Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).

Before prescribing Glimepirida Mabo, clinicians should evaluate several patient‑specific factors to minimize risk.

- Assess renal and hepatic function; dose adjustment may be needed in impairment. - Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning. - Use caution in elderly patients due to increased hypoglycemia risk. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Monitor blood glucose regularly, especially when initiating therapy or changing dose. - Consider potential for weight gain and adjust lifestyle counseling accordingly.

Glimepirida Mabo can interact with other medicines, influencing its glucose‑lowering effect or increasing adverse reactions.

Avoid: - Concomitant use with other sulfonylureas or insulin, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - MAO‑B inhibitors (e.g., selegiline) that may potentiate hypoglycemia.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect glucose tolerance. - Corticosteroids or atypical antipsychotics that may increase blood glucose, requiring dose adjustments.